AngloGold Ashanti Limited vs Nuwellis Inc — how do they compare? AngloGold Ashanti Limited trades at $100.45 (market cap $49.19B), while Nuwellis Inc trades at $1.48 (market cap $522.76K). The key difference: AngloGold Ashanti Limited is far larger — about 94096.7× Nuwellis Inc's market cap, and AngloGold Ashanti Limited pays a 4.65% dividend while Nuwellis Inc pays none. Which is the better fit depends on your goals.
| AU | NUWE | |
|---|---|---|
Market Cap | $49.19B | $522.76K |
Sector | Basic Materials | Technology |
52-Week High | $128.26 | $220.50 |
52-Week Low | $52.15 | $1.42 |
Enterprise Value | $48.20B | -$1.29M |
Dividend Yield | 4.65% | — |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
NUWE trades at $1.49, down 8.59% over the past day, with a bearish technical outlook. The company reported a net loss of $17.52M in 2025, with a negative net income margin of -217.22%, though it has shown revenue growth and recent strategic expansions in pediatric care. A recent 35:1 reverse stock split was executed on June 26, 2026.
The outlook remains high-risk due to persistent losses and cash burn, but growth initiatives and new product development offer potential. Key risks include execution challenges and dependence on financing. Analyst sentiment is mixed, with a 50% buy and 50% hold rating among covered analysts.
Trailing returns across standard periods
Anglogold Ashanti Ltd is one of the largest gold miners. The company also produces silver and sulphuric acid as by-products. Its operating divisions are Africa, Australia, and the Americas. The firm generates a majority of its revenue from Africa which includes Ghana, Guinea, Mali, the Democratic Republic of the Congo, and Tanzania.
Read more on AU →Nuwellis, Inc. is a medical device company focused on developing and commercializing fluid management solutions. The company's primary product is an ultrafiltration system used in hospitals to remove excess fluid from patients with fluid overload, often associated with conditions such as heart and kidney failure. Nuwellis aims to improve patient outcomes and reduce healthcare costs through its specialized, innovative therapies.
Read more on NUWE →